Price Target Update on Gilead Sciences (NASDAQ:GILD)

Gilead Sciences (NASDAQ:GILD) : Currently there are 14 street experts covering Gilead Sciences (NASDAQ:GILD) stock. The most bullish and bearish price target for the stock is $135 and $96 respectively for the short term. The average price target of all the analysts comes to $115.71. The estimated standard deviation from the target is $11.72.

Other Equity analysts have also commented on the company shares. Gabelli & Co initiates coverage on Gilead Sciences (NASDAQ:GILD) . Analysts at the Gabelli & Co have a current rating of Buy on the shares. The rating by the firm was issued on June 1, 2016.

Gilead Sciences (NASDAQ:GILD): stock turned positive on Thursday. Though the stock opened at $83.29, the bulls momentum made the stock top out at $83.575 level for the day. The stock recorded a low of $82.54 and closed the trading day at $83.37, in the green by 1.12%. The total traded volume for the day was 5,843,954. The stock had closed at $82.45 in the previous days trading.

The company shares have dropped -31.42% from its 1 Year high price. On Jun 25, 2015, the shares registered one year high at $122.61 and the one year low was seen on May 19, 2016. The 50-Day Moving Average price is $84.62 and the 200 Day Moving Average price is recorded at $91.47. On the companys insider trading activities,The director officer (President and CEO) of Gilead Sciences Inc, Milligan John F sold 112,000 shares at $86.92 on June 6, 2016. The Insider selling transaction had a total value worth of $9,735,040. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.

Gilead Sciences, Inc. (Gilead), is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV), liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection, oncology and inflammation, and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. Its Liver Diseases products include Harvoni, Sovaldi, Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.